TMCnet News
Research and Markets: Anti-obesity Drugs Market in the US 2015-2019 - Diversification of Investigational PipelineResearch and Markets (http://www.researchandmarkets.com/research/hjbp4g/antiobesity) has announced the addition of the "Anti-obesity Drugs Market in the US 2015-2019" report to their offering. The anti-obesity drugs market in the US to grow at a CAGR of 24.52% over the period 2014-2019. The report covers the present scenario and the growth prospects of the anti-obesity drugs market in the US for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of the currently approved patented drugs, generics, OTC products, and the available generics that are used for the treatment of obesity. The report, Anti-obesity Drugs Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers themarket landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. Key Vendors - Arena Pharmaceuticals - F. Hoffmann-La Roche - GlaxoSmithKline - Novo Nordisk - Orexigen Therapeutics - Vivus Other Prominent Vendors - Alizyme - Amylin - Boehringer Ingelheim - Eisai - Merck - Norgine - Pfizer - Rhythm Pharmaceuticals - Shionogi USA - Takeda Pharmaceutical - Zafgan Key Topics Covered:
For more information visit http://www.researchandmarkets.com/research/hjbp4g/antiobesity
View source version on businesswire.com: http://www.businesswire.com/news/home/20150831005684/en/ |